CompletedNCT01955564
A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers.
Medication studyAges 18–45United StatesSchizophrenia
Understand this study
Who was this study for?
Listed age limits: 18 years to 45 years.
- Listed locations
- Long BeachSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateJune 2013
- Recruitment status
- Completed
- Enrollment listed in the registry
- 54
- Sponsor
- Newron Pharmaceuticals SPA
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 18 Years to 45 Years
- Official registry ID
- NCT01955564
- Official title
Show the full official title
A Phase I, Prospective, Randomized, Double-blind, Placebo-controlled, Sequential-cohort, Escalating, Single-dose Study Designed to Determine the Maximum Tolerated Oral Dose of NW-3509A in Healthy, Male Volunteers.
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Long Beach
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Newron Pharmaceuticals SPA.
Did this study involve medication?
Yes. The study involved medication, including NW-3509a.
Who was this study for?
Listed age limits: 18 years to 45 years.
